LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances
1 source
·3h ago
Biological Products, (No Diagnostic Substances) · US
In the news · 2
Recent filings
Actual SEC filing dates from EDGAR.
More in Healthcare